Global Home Global Home  

Board of Directors

Ms. Barbari has served as Executive Vice President of Finance and Chief Financial Officer of Cytokinetics Inc. since July 2009. She served as Senior Vice President of Finance and Chief Financial Officer from September 2004 through June 2009. From September 2002 to August 2004, Ms. Barbari served as Chief Financial Officer and Senior Vice President of Finance and Administration of InterMune, Inc., a biopharmaceutical company. From January 1998 to June 2002, she served at Gilead Sciences, Inc., a biopharmaceutical company, and held several positions of increasing responsibility including most recently as its Vice President and Chief Financial Officer. From 1996 to 1998, Ms. Barbari served as Vice President of Strategic Planning at Foote, Cone & Belding Healthcare in San Francisco, an international advertising and marketing firm. From 1972 to 1995, she was employed by Syntex Corporation where she held various management positions in corporate finance, financial planning, marketing and commercial planning.

Jay Birnbaum has served as a director since April 2007. Dr. Birnbaum is a co-founder and former Chief Medical Officer of Kythera Biopharmaceuticals and a co-founder and Chief Scientific Officer of Hallux, Inc. Prior to starting his own consulting company in 1999, he was Vice President, Global Project Management, at Novartis Pharmaceuticals, where he also had responsibilities for strategic planning and development of the company's dermatology portfolio.  Previously, he held various management positions at Sandoz/Novartis and at both the Medical and Consumer Product Divisions of American Cyanamid Company (Wyeth). In addition to his consulting practice, he is currently Executive Vice President Global Product Development at Thesan Pharmaceuticals. He has served on the board of directors of Excaliard Pharmaceuticals (acquired by Pfizer) and on the scientific advisory boards of several companies.

He received both an M.S. and Ph.D. in pharmacology from the University of Wisconsin and a B.S. in biology from Trinity College in Connecticut.

Mr. McLaughlin served as Interim Chief Executive Officer of Applied BioCode, Inc. from November 2011 to April 2013. In April 2011, he also founded and currently serves as Chairman and Chief Executive Officer, of DataStream Medical Imaging Systems, Inc., a start-up to develop diagnostic imaging software applications that work in conjunction with existing digital radiology platforms. He previously served as President of DataFlow Information Systems, from July 2007 to December 2011, and President and Chief Executive Officer of CompuMed, Inc. from May 2002 to June 2007. Mr. McLaughlin also serves on the board of directors of DataStream Medical Imaging Systems, Inc., a private company in the medical imaging software industry.

Mr. Weigerstorfer brings extensive pharmaceutical and dermatology experience to Sonoma’s board with a track record of expanding businesses around the globe. He began his career in marketing at Sandoz and Novartis, advancing to marketing and business leader roles for cardiovascular, dermatology and other global business units. During this time, he helped develop and launch highly successful brands such as Lamisil, Apligraf and Elidel. In 1999, Weigerstorfer joined Galencia Ltd’s executive team where he led the retail, pre-wholesale, business development and M&A divisions. Philippe was a key leader in transforming Galencia from a Swiss-based wholesaler to a player in the international healthcare market.


James Schutz served as our vice president of corporate development and general counsel since August 2003, as a director since May 2004 and corporate secretary since June 2006. He was appointed CEO in February 2013.  Mr. Schutz was formerly the general counsel of Jomed, Inc. until 2003 when he orchestrated the sale of Jomed to Abbott Laboratories (NYSE: ABT) and Volcano Therapeutics (NASDAQ: VOLC, now part of Royal Philips, NYSE PHG). Mr. Schutz received a B.A. in economics from the University of California, San Diego and a J.D. from the University of San Francisco School of Law.